How parallel startup activities, early patient identification, and sponsor-CRO collaboration accelerated activation and randomization in a priority cardiology trial
When a clinical trial is designated as a corporate priority for accelerated startup, every stage of site activation becomes time-sensitive.
For one cardiology study, the sponsor identified rapid startup as a priority, requiring Profound Research to move efficiently through regulatory approvals, training, activation, and patient recruitment while maintaining study quality.
Profound responded by advancing key startup activities simultaneously. IRB approvals and system training moved forward in parallel, while patient pre-pooling and recruitment preparation positioned the site to identify qualified participants quickly once enrollment could begin.
Working collaboratively with the sponsor and CRO, Profound achieved the agreed-upon accelerated activation timeline and randomized the study’s first patient just 27 business days after CTA execution.
The Challenge: Accelerated Startup for a Sponsor-Priority Study
From the outset, the sponsor identified the study as a corporate priority requiring accelerated startup.
That placed additional emphasis on the site’s ability to move efficiently through the activities required for activation while maintaining the quality and accuracy expected throughout the startup process.
The challenge extended beyond reaching activation quickly. To translate accelerated startup into meaningful study progress, the site also needed to be prepared to identify qualified participants and move toward randomization once enrollment opened.
The Solution: Parallel Startup and Early Patient Preparation
Profound leveraged its experience and resources to accelerate multiple startup activities simultaneously.
The team expedited the IRB approval process while initiating required system training in parallel, helping reduce delays between individual startup workstreams and support rapid site activation.
Patient recruitment preparation also began early. Through pre-pooling of potential participants and an expedited rollout of recruitment activities, the team positioned the site to identify qualified candidates quickly.
Rather than waiting until activation to begin preparing for enrollment, these efforts allowed startup and patient-readiness activities to progress alongside one another.
Close coordination with the sponsor and CRO supported the process as Profound worked toward the agreed-upon accelerated site activation date.
The Outcome: First Patient Randomized in 27 Business Days
Profound successfully navigated the regulatory and operational requirements necessary to meet the accelerated activation timeline without sacrificing quality.
Following activation, the site’s early patient preparation helped move the study rapidly toward enrollment, culminating in the first patient in the study being randomized 27 business days after CTA execution.
Key Study Achievements:
- Kickoff: Feasibility received
- Month One: CRO/site selection process
- Month Two: Site selection; contract and budget execution
- Month Three: SIV completed; regulatory and IRB approval secured; site activated
- 27 business days from CTA execution: First patient randomized
The result demonstrates how parallel startup activities, early patient preparation, and collaboration among the site, sponsor, and CRO can translate an accelerated activation strategy into meaningful enrollment progress.
What This Means for Sponsors
Accelerated startup creates the most value when speed to activation is paired with readiness to enroll.
In this cardiology study, Profound advanced regulatory approvals and system training simultaneously while beginning patient pre-pooling and recruitment preparation ahead of activation. As a result, the site was not only positioned to meet the sponsor’s accelerated activation target, but also prepared to identify qualified participants and move quickly toward randomization.
For sponsors and CROs managing priority studies, this approach demonstrates the value of coordinating startup and recruitment activities rather than treating them as entirely separate phases.
By preparing operational workstreams and potential patient recruitment in parallel, sites can help reduce the time between contract execution, activation, and meaningful study enrollment.
Looking Ahead
Accelerating clinical trial startup requires more than completing individual tasks quickly. It requires coordination across regulatory, operational, training, and recruitment activities so that progress in one area supports progress in another.
For this sponsor-priority cardiology trial, Profound worked collaboratively with the sponsor and CRO to meet the agreed-upon accelerated site activation date while preparing for recruitment in parallel.
The result: first patient randomized just 27 business days after CTA execution – demonstrating how coordinated startup and early patient preparation can help move priority studies from contracting to enrollment efficiently without sacrificing quality.